3SBio (1530.HK) Osake Kurssi
3SBio Kurssi
Liikevaihto on kasvanut 29,6 % vuodessa viimeisten 19 vuoden aikana 20,61 Mrd. CNY:een. Osakekohtainen tulos on kasvanut 13,8 % vuodessa viimeisten 13 vuoden aikana. 3SBion nettomarginaali on nyt 47,9 %, noussut 25,9 %:sta muutama vuosi sitten. 3SBion osinkotuotto on tällä hetkellä noin 1,97 %. Jakosuhde on noin 5 % tuloksesta. Osinko on kasvanut 20,3 % vuodessa viimeisten 7 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 32,59 CNY, eli yli nykyhintaa 157,2 %. 18 analyytikosta 16 suosittaa ostoa — kokonaiskonsensus on Osta.
3SBio osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
3SBio liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset 3SBio -osakkeesta
3SBio Inc operates as a leading biotechnology company. The business model of 3SBio Inc revolves around the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology, nephrology, and autoimmune diseases. By leveraging their expertise in biologics and in-house manufacturing capabilities, 3SBio Inc aims to deliver high-quality and affordable medicines to patients worldwide. With a commitment to advancing healthcare, 3SBio Inc continues to invest in R&D efforts and strategic partnerships, aiming to improve patient outcomes and enhance their market presence.
3SBio Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of 3SBio Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis International AG, Amgen Inc, and Roche Holding AG.
3SBio Inc is a leading biotechnology company specializing in the research, development, and manufacturing of innovative biopharmaceutical products. Founded in 1993, the company has a rich history in the biotech industry. With its headquarters in China, 3SBio Inc has expanded globally and gained recognition for its expertise in therapeutic areas including nephrology, oncology, and immunology. The company is committed to improving patient outcomes through the development of high-quality, life-saving medications. 3SBio Inc has established itself as a trusted name in the biopharmaceutical sector, delivering innovative solutions to address unmet medical needs and improve the quality of life for patients worldwide.
3SBio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2015, marking a major milestone in its history. Furthermore, 3SBio Inc has seen remarkable growth and success in the biopharmaceutical industry, particularly in the development and commercialization of innovative medicines. They have obtained regulatory approvals for various products, expanded their product portfolio, and established strategic partnerships to enhance their market presence. The company's dedication to research and development has also resulted in numerous scientific achievements and breakthroughs. Overall, 3SBio Inc has demonstrated consistent progress and remains a leading player in the biopharmaceutical sector.
3SBio Inc is primarily present in China and the United States.
3SBio Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. The company values putting patients first and developing high-quality therapeutic solutions. With a focus on research and development, 3SBio Inc is dedicated to discovering, developing, and commercializing innovative biopharmaceutical products. The company's corporate philosophy centers around offering effective and affordable treatments to improve patients' lives. By staying true to their core values, 3SBio Inc aims to make a positive impact on healthcare and contribute to the well-being of individuals worldwide.
Analyytikot asettavat tällä hetkellä 3SBio-osakkeelle keskimääräisen tavoitehinnan 33,12 CNY (mediaani: 32,59 CNY), mikä merkitsee +161,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 18 analyytikkoarvioon.
18 analyytikkoa arvioi tällä hetkellä 3SBio-osaketta: 16 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat 3SBio-yhtiöltä 9,54 Mrd. CNY liikevaihtoa ja 0,95 CNY osakekohtaista tulosta.
Nykyisellä valuuttakurssilla 3SBio-osake noteerataan hintaan 1,69 EUR (12,67 CNY).
3SBio-osake (1530.HK) on listattuna 5 pörssissä, muun muassa: Hongkong (HKEX) (1530.HK), Frankfurt (83B.F), München (83B.MU), Düsseldorf (83B.DU).
The Chinese company 3SBio Inc is a leading company in the biopharmaceutical industry, specializing in the development, manufacturing, and marketing of biological drugs. 3SBio focuses on the areas of oncology, immunology, nephrology, and infectious diseases. The main products of 3SBio include biosimilars of innovative drugs such as rituximab, enoxaparin, adalimumab, darbepoetin alfa, pegaspargase, and etanercept. Biosimilars are biologically manufactured drugs that have similar active ingredients as original biologics and thus provide a more cost-effective alternative. 3SBio has the largest market share for biosimilars in China and continually expands its portfolio. In addition to biosimilars, 3SBio also offers innovative biological drugs. One example is Tpiao, a recombinant human thrombopoietin receptor agonist. It is used to treat thrombocytopenia in patients with hepatitis B or hepatitis C infections. Another important area for 3SBio is nephrology. The company has various products in its portfolio that are used to treat kidney diseases. These include, for example, the erythropoiesis-stimulating agent (ESA) ferumoxytol, which is used to treat iron deficiency anemia in chronic kidney disease, as well as binodenoson, an adenosine receptor agonist used for diagnostic imaging of kidney diseases. The business model of 3SBio Inc is based on the acquisition of promising technologies, its own research and development work, and the manufacturing and marketing of biological drugs. The company works closely with regulatory authorities and health organizations to achieve fast market approval for its products. An important aspect is also international distribution. 3SBio strategically enters growth markets in Asia, especially in China, and expands into other parts of the world. Through partnerships with other companies and the acquisition of firms in the biopharmaceutical industry, 3SBio continuously expands its value chain and its portfolio. Overall, 3SBio pursues a diversified business model based on the utilization of synergies in the areas of research, development, manufacturing, and marketing of biological drugs. By utilizing biosimilars and innovative active ingredients, the company has achieved high competitiveness and is on a path of expansion.
odotettu liikevaihto 3SBio on 9,54 Mrd. CNY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto 3SBio on 2,37 Mrd. CNY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
3SBio:n hinta-voitto-suhde (P/E) on tällä hetkellä 13,28. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan 3SBio-osakkeen arvostusta.
3SBio:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,30. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii 3SBio-osakkeen arvostuskennuslukuna.
3SBio:n Eulpool-laatuscore on 8/10.
3SBio:n ISIN on KYG8875G1029. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
3SBio:n WKN on A14T7Q. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
3SBio:n ticker on 1530.HK. Tämä pörssinoteeraus käytetään 3SBio-osakkeiden kauppaan pörssissä.
3SBio osake
Kaikki tunnusluvut ja syvällinen analyysi 3SBio:sta
Meidän osakeanalyysimme 3SBio-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut 3SBio:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: